Dutch bispecific antibody developer nets $18.7 million from US, European VCs
Lava Therapeutics nets 16 million euros in Series B round and plans to decide on clinical drug candidate in oncology this year.
‘S Hertogenbosch
Lava Therapeutics nets 16 million euros in Series B round and plans to decide on clinical drug candidate in oncology this year.